The doc social Morning Brief is a short daily briefing on the news that actually changes how surgeons and the people who support them work: reimbursement and policy, device clearances and recalls, guideline changes, and the commercial shifts behind them.
It is written for an audience that already knows the clinical fundamentals, so it skips the explainer and goes to what is new — where a device sits against what already exists, what a rule change does to a real clinic day, and what is worth doing about it this week.
Produced by doc social. Narration is synthesized; the reporting and editorial judgement are ours, and every story is sourced.
Episodes
48 total · newest first
Press play on any episode and the show keeps running from there.
Bioventus Q3 2026: revenue $142.4M (+2.7%); Pain Treatments +6.2% on Durolane, PRP and PNS; Surgical Solutions +0.7% (U.S. -2.8%) on softer bone graft substitutes; Restorative Therapies -3.4% on EXOGEN; FY26 net sales guidance cut to $590-595M from $600-610M; adjusted EPS $0.75-0.79 reaffirmed; strategic alternatives review (opened Aug 5 after an unsolicited proposal) continues · Highridge Medical, the former ZimVie spine business owned by H.I.G. Capital, names Rob Fredericks CEO (ex-Lighteum Medical, Merit Medical, C.R. Bard; spine experience at Medtronic); Eric Major remains executive chairman · Bone Joint J, Norwegian Arthroplasty and Hip Fracture Registers: in 204,041 primary hip arthroplasties (2005-2025), reoperation for periprosthetic femoral fracture in men was ~9x higher with polished taper-slip and uncemented collarless stems and ~4x with uncemented collared stems vs cemented composite-beam stems; age thresholds for excess risk differed by sex and design · J Arthroplasty double-blind RCT, 86 primary TKA patients: extended oral tranexamic acid (1.95 g/day POD 1-3) after standard IV TXA did not improve VAS pain at any point to 12 weeks, ROM, opioid use or ambulation vs placebo
SI-BONE Q3 2026: revenue $55.7M (+14.5%), U.S. $52.8M (+13.9%) on ~19.5% procedure growth offset by lower ASP from mix and office/ASC INTRA demand; 1,770 active U.S. physicians (+~16%); adjusted EBITDA $3.0M; FY26 revenue guidance of $231-233M reaffirmed; iFuse Granite Onyx in alpha launch · Medartis says U.S. adoption of the TOUCH CMC 1 thumb prosthesis is accelerating: more than 2,000 U.S. procedures by October and about 3,000 expected in 2026; expects to beat its 17-19% organic core growth guidance · Br J Anaesth RCT, Samsung Medical Center: remimazolam-based TIVA with flumazenil reversal noninferior to propofol-based TIVA for postoperative delirium after elective neurovascular surgery (12.8% vs 10.8%, 686 patients), with less hypotension and more extubation in the OR (85.2% vs 67.3%) · Bone Joint J meta-analysis of 22 RCTs (28,112 patients): DOACs lowered VTE vs LMWH after elective THA (OR 0.62); overall bleeding higher (OR 1.19) but no difference with UK-licensed agents and doses (OR 1.06); no difference in reoperation or mortality
Stryker Q3 2026: net sales $6.5B, organic +7.7%; knees +1.2% and hips -0.7% in constant currency; FY26 organic growth guidance cut to 6.5-7.0% (from 8.3-9.3% in July) and adjusted EPS to $14.80-14.90 (from $14.95-15.10) · ATEC (Alphatec) Q3 2026: revenue $221M (+13%), surgical $202M (+14%), case volume +~20%, net new surgeon users +25%, hardware +17%; short of expectations on lower biologics attachment; FY26 revenue guidance lowered to ~$862M from ~$882M · BMJ, FIRST RCT: 430 patients at 26 UK hospitals after zone 1-2 flexor tendon repair; no significant difference in PRWHE over a year between forearm-based, Manchester short and relative motion flexion splints · BMJ, Inject RCT: 192 adults with midportion Achilles tendinopathy; high-volume injection with or without hydrocortisone no better than sham on VISA-A at 12 months; steroid arm better at 6 weeks but worse than steroid-free arm at 26 weeks
OrthoPediatrics Q3 2026: record revenue $72.7M (+19%; US +19%, international +18%), Trauma & Deformity $52.6M (+19%), Scoliosis $19.2M (+18%), adjusted EBITDA $6.9M, free cash flow +$1.6M; FY26 revenue guidance raised to $270-273M; same day, FDA 510(k) clearance and first cases for the PNP Retrograde femoral nail · Axogen Q3 2026: revenue $75.8M (+26.2%), gross margin 74.8% (vs 76.6%), FY26 guidance raised to at least $290M (+29%) including at least $7M from BioCircuit/NerveTape (closed Oct 1 for $200M cash); Elevance and Aetna positive coverage for Avance, commercial coverage ~96% of US covered lives; prostate market development from 2027 · J Arthroplasty, prospective Greek study: an intraoperative synovial calprotectin point-of-care lateral flow test (cutoff 50 mg/L) in 80 hip and knee revisions had sensitivity 91.7% / specificity 90.3% in THA (24 PJI of 55) and 87.5% / 100% in TKA (8 PJI of 25) against 2018 ICM criteria · J Arthroplasty, Danish Hip Arthroplasty Register: 10-year standardized all-cause revision 6.6% with monoblock dual-mobility cups (n=5,187) vs 5.9% with 36 mm heads (n=35,162) and 6.9% with 32 mm heads (n=15,702) in primary THA for OA, 2007-2019; no significant difference; DM lower revision for dislocation, higher for infection
HealthSpan Partners, a Bon Secours Mercy Health affiliate, agrees to acquire Surgery Partners in an all-cash deal at ~$5.7B enterprise value: $23.50/share (64% over 30-day VWAP; ~49% over the Oct 23 close of $15.75); Bain Capital (~39%) rolls over; 200+ locations in 30 states, ~5,000 affiliated physicians; close expected Q1 2027; $109.0M company termination fee · J Shoulder Elbow Surg, New Zealand Joint Registry: in 8,601 primary reverse shoulders (2007-2024), polyethylene glenospheres had fewer revisions than metal (0.46 vs 0.71 per 100 component-years; adjusted HR 0.57), with similar Oxford Shoulder Scores to 10 years · AO Spine Knowledge Forum Degenerative publishes clinical practice recommendations for interbody fusion at the lumbosacral junction: ALIF preferred when more lordosis is needed; stand-alone ALIF comparable to 360 in selected patients; ALIF plus percutaneous screws for isthmic spondylolisthesis when feasible
FDA device center director Michelle Tarver: about 22% staff attrition over the past year and a half, up to 30% of clinical reviewers lost; 65 hires at White Oak beat the FY26 MDUFA goal of 63; 151 novel devices authorized in FY26; MDUFA VI targeted to Congress by January 2027 · J Arthroplasty microsimulation: US orthopaedic surgeon supply falls 1.7% by 2038 under status quo; adequacy 79.5% in the South vs 102% in the Northeast, and 48.8% in non-metro vs 94.0% in metro areas · Spine J, European Spine Study Group: rod breakage in 30 of 83 adult spinal deformity fusions to the pelvis over ~5 years; titanium HR 0.50 vs cobalt-chromium, diameter >5.5 mm HR 1.90, L4-S1 rod curvature >=33 degrees at 6 weeks HR 2.25 · ESRA PROSPECT recommendations for pain after total shoulder arthroplasty: acetaminophen, NSAID, IV dexamethasone 8-10 mg, single-shot interscalene with plain bupivacaine or ropivacaine (not liposomal); local infiltration as the alternative
Integra LifeSciences Q3: revenue $411.2M (+2.5% organic) with Neuro up 6.5% organic, Tissue Reconstruction down 2.2%, a ~$7M Cincinnati flood hit, lowered FY26 revenue guidance, and a $2.1B refinancing including $450M of 9.5% secured notes · Total Joint Orthopedics takes a Wells Fargo debt facility of up to $11 million to fund implant inventory, instrument sets, distribution and its cobalt-chrome-free Aurum designs · JAMA, PELICAN RCT: individualized cardiac index-guided hemodynamic therapy did not reduce a 7-day composite of complications or death vs routine care in 1,095 high-risk patients having elective major abdominal surgery
Constitution Surgery Alliance enters Michigan by partnering with UnaSource Surgery Center and MiOrtho Surgery Center, the ASC founded by Michigan Orthopaedic Surgeons · FDA classes Philips' Lumify handheld ultrasound correction as a Class I recall: the app can demand transducer re-registration without warning, blocking scanning until it gets a network signal · Anesthesiology, ORACLE: in a blinded cluster-randomized trial of 110,538 surgeries in 68 operating rooms, supplemental air purification did not reduce surgical infections; stopped for futility · J Orthop Trauma RCT at 19 US trauma centers: weight bearing at two weeks after ankle fracture fixation was noninferior to six weeks for reoperation, but did not significantly speed return to work
Intuitive's Q3: revenue up 22% to $3.05B on ~14% da Vinci procedure growth and 546 system placements, plus a $450M charge to settle the hospital antitrust class action over instrument service and repair · Synergy Spine's PERFORM real-world study at NASS 2026: 120 single-level Synergy Disc patients at five UK, EU and Australian sites, 30% with same-surgery ACDF, NDI 43.4 to 9.5 at one year, no explants or device-related adverse events · J Neurosurg Spine, RWTH Aachen: in 725 navigated screws in 121 patients, planned-versus-achieved trajectory divergence was largest in the subaxial cervical spine (4.2 degrees axial) and barely tracked misplacement; 95% of screws were acceptable · J Arthroplasty, Rush: preoperative SSRI use tied to more two-year complications after primary THA (5.2% vs 3.2%) in 77,958 matched users, with no dose-response
Youngstown Orthopaedic Associates joins Cleveland Clinic November 1 while Southwoods Health sues two of its surgeon-shareholders over a 30-mile non-compete · TLC BioSciences' TLC590, an extended-release ropivacaine, beats placebo and liposomal bupivacaine on 72-hour pain and opioid use in a 304-patient Phase 3 bunionectomy trial · Spine J, Virginia Mason: prone and lateral-decubitus single-level L4-5 LLIF cost about the same intraoperatively, but supply mix differs and biologic share ranged from about 5% to 19% across three surgeons
STERIS agrees to buy Xodus Medical, maker of Pink Pad positioning products, for $2.1 billion in cash plus up to $150 million in 2028 earnouts · Providence Medical Technology gets FDA 510(k) clearance for CORUS PCSS 3D-T, a 3D-printed porous titanium version of its posterior cervical stabilization system, debuting at NASS · JBJS RCT, 80 arthroscopic shoulder patients: surgeon-performed shoulder field anesthesia noninferior to interscalene block on cumulative 48-hour pain, with no Horner syndrome or respiratory events
J&J says DePuy Synthes separation remains on track for mid-2027 and it is leaning toward a spin-off; Q3 orthopaedics sales rose 3.2% to $2.34B while spine fell 0.9% · Kuros Biosciences raises 2026 guidance to 36-40% sales growth after nine-month sales of $141.8M (+40%) and starts MagnetOs production in Alpharetta, Georgia · Amber Implants begins the U.S. introduction of its VCFix Spinal System, a pedicle-based expandable implant with cement for vertebral compression fractures · HSS registry study at NASS 2026: robotic-arm MIS-TLIF associated with 16% lower in-hospital opioid use than navigation-guided MIS-TLIF in 804 patients
FDA approves two-level use of Centinel Spine's prodisc C Nova, making three of Centinel's four cervical discs labeled for one or two contiguous levels · Zimmer Biomet and THINK Surgical sign a multi-year extension of their exclusive distribution deal for a Persona-compatible version of the TMINI handheld knee robot · Patient-specific spine at NASS: Carlsmed starts the full U.S. launch of its aprevo lumbar bi-lateral posterior system as Globus previews its FDA-cleared SCRIPT patient-specific platform · JBJS: 791 anatomic total shoulders from Florida Orthopaedic Institute show 96% implant survival at 10 years, but 69.5% of shoulders at the patient-acceptable threshold
Stryker makes a roughly $400 million preferred equity investment in CMR Surgical, with an exclusive option to buy all of it, and becomes exclusive U.S. sales agent for the Versius soft-tissue robot · Shoulder Innovations begins a limited user release of InSet Go, its next-generation inset anatomic glenoid, after a first case at University Hospitals Cleveland · Bone & Joint Journal, Belgian single-centre propensity-matched study of 780 uncemented THAs: dual mobility had about one-tenth the dislocations of ceramic-on-ceramic but three to five times the femoral periprosthetic fractures
DePuy Synthes signs a U.S. sales agency agreement with SMAIO for the KEOPS-4ME planning platform and patient-specific K-ROD rods · FDA grants De Novo to Brixton Biosciences' ReneuRx (Neural Ice), an injectable cold slurry for knee OA pain, creating a new Class II category · Anesthesia & Analgesia RCT, 180 PLIF patients: deep neuromuscular block cut 3-month chronic postsurgical pain from 34.8% to 19.1% versus moderate block; no significant difference at 6 months · J Neurosurg Spine, CSM-Protect secondary analysis: dysphagia after multilevel anterior surgery for cervical myelopathy peaked at 68.6% and was still 36.4% at one year
CMS posts the CJR-X participant list: 2,217 hospitals in a mandatory 90-day hip, knee and ankle bundle starting January 1, 2028 · SurGenTec takes an exclusive license to Allevion Medical's Vantage, a fully disposable lumbar decompression kit cleared in March as K252546 · FDA 510(k) clears Mass General's GSPE Spacer, a gentamicin-loaded UHMWPE temporary knee spacer for two-stage PJI; commercial license still pending · JBJS Yale RCT in primary THA: anterior QLB plus LFCN block vs periarticular/local infiltration, both with dual glucocorticoids, no difference in day-one opioids
Centinel Spine files publicly for a NYSE IPO under CNTL: first-half 2026 revenue $85.2M (+42%), net income $10.2M, pure-play prodisc total disc replacement · MRI2CT announces FDA 510(k) clearance for NextMR Spine, cloud software that generates 3D lumbar spine and sacrum bone images from standard MRI, entering a category MRIguidance's BoneMRI has held since 2022 · Smith+Nephew launches CARTIHEAL AGILI-C in 12 European markets ahead of the ICRS Summit in Porto, on five-year RCT data against microfracture and debridement · KSSTA, Bridge registry two-year results for Miach's BEAR implant: 5.6% ipsilateral ACL retear, none in year one, but 18.9% overall reoperation (28.0% original vs 7.5% modified technique)
icotec's CMORE CT carbon/PEEK cervicothoracic system gets a Medicare new technology add-on payment, up to $60,905 per case, for fusion use only · Stryker names Spencer Stiles CEO effective January 1, 2027; Kevin Lobo becomes Executive Chair · Neurosurgical Focus, pooled analysis of two randomized trials (211 patients): wound dehiscence 0% after biportal endoscopic vs 8.7% after microscopic single-level lumbar decompression
Pacira licenses EXPAREL to Molteni Farmaceutici for the EU and UK; Italy, Germany, Austria and Poland first, first commercial sale expected in 2027 · Spine RCT, 70 patients with grade III-IV spondylolisthesis: extending L4-S1 fixation to S2 or S2AI cut S1 screw breakage from 66% to zero and improved 36-month pain and ODI · Spine, Houston Methodist: screening ligamentum flavum at lumbar decompression found transthyretin amyloid in 20% of 50 selected patients
AMA CPT Editorial Panel votes a Category I code for posterior vertebral column arthroplasty, covering Premia Spine's TOPS facet replacement, effective January 1, 2028 · J Neurosurg Spine, Washington State Spine COAP registry: intrawound antibiotics not associated with fewer surgical site infections across 24,015 instrumented spine cases · CORR target trial emulation of 4,564 Japanese periprosthetic hip fractures: no clear 30- or 90-day mortality difference between surgery within two days and surgery on days three to ten
PearlMatrix P-15 peptide bone graft's Medicare new technology add-on payment goes live October 1 — TLIF use only, capped at $3,380, alongside INFUSE's $4,396.60 TLIF add-on · Tenon Medical takes the 3D-printed titanium lateral screw in its SImmetry+ SI joint fusion system to full commercial launch after a ~$1.2M alpha · JBJS: revision hip and knee volume across 17 registry countries projected to rise ~36% by 2060, led by the US and China · BMJ, UK National Joint Registry target trial emulation: robotic and conventional hips and knees show equal five-year implant survival; robotic hips had about half the malposition-related revisions
Terumo Neuro signs to acquire Arsenal Medical and its investigational NeoCast liquid embolic for middle meningeal artery embolization, now in a pivotal trial head to head against Onyx · Sharp HealthCare becomes a strategic equity partner in the DISC Surgery Center at Carlsbad, a spine-heavy ASC, three months after taking over Tri-City Medical Center · Two rib fixation entrants in one week: Chest Wall Innovations launches PC Fix, with an intrathoracic PEEK option, and GMReis announces 510(k) clearance for VersaLock rib and sternum plates · NEJM publishes TRIUMPH-1: retatrutide cut weight by up to 25% at 80 weeks and reduced WOMAC knee pain 1.6 to 1.8 points more than placebo in 574 participants with knee osteoarthritis
Carlsmed appoints former ZimVie CFO Richard Heppenstall as chief financial officer and reaffirms 2026 revenue guidance of $74 to $78 million ahead of the October 1 aprevo payment policy · VB Spine receives FDA Breakthrough Device Designation for ScolimiR-3D, a six-microRNA blood test to predict adolescent idiopathic scoliosis progression · Anesthesiology: in 258,624 Ontario hip and knee arthroplasties, a new extended-release opioid prescription at discharge was associated with more persistent opioid use, readmissions and ED visits · OTA 2026 randomized trial: local aqueous tobramycin added to IV antibiotics did not reduce infection in 569 open extremity fractures
FDA issues draft guidance on premarket submissions for robotically-assisted surgical devices; orthopedic (OLO) and neurological (HAW) stereotaxic systems are explicitly out of scope; comments due November 24, 2026 · Avesi Partners invests in New Age Medical, a St. Louis spine supply hub linking 85+ manufacturers, 100+ reps, 200+ hospitals/ASCs and 350+ surgeons, to fund expansion, new specialties and M&A · SI-BONE receives FDA 510(k) clearance for iFuse Granite Onyx, aimed at screw loosening at the UIV and LIV of spinal fusion constructs in low-density bone · HSS cohort at EBJIS-MSIS 2026: extended oral antibiotics after two-stage TKA reimplantation did not reduce PJI-related reoperation in 2,181 patients
